The results of the STOPDAPT-3 trial, a Japanese multicenter trial, were presented at the Hot Line session of ESC 2023. The trial compared single-agent prasugrel antiplatelet therapy with dual antiplatelet therapy (DAPT) after PCI using DES in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR). No superiority was observed in controlling severe bleeding, and non-inferiority was demonstrated in the evaluation of cardiovascular events.

TCROSS NEWS spoke with Dr. Masahiro Natsuaki of Saga University, who conducted the trial, about the background of the trial, the types of patients for whom the aspirin-free strategy is suitable, and the impact of differences in DES on the results.